Loading...
Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma
BACKGROUND: Dasatinib (Sprycel) was developed as a tyrosine kinase inhibitor targeting Bcr-Abl and the family of Src kinases. Dasatinib is commonly used for the treatment of acute lymphoblastic and chronic myelogenous leukemia. Previous clinical studies in melanoma returned inconclusive results and...
Na minha lista:
| Udgivet i: | BMC Cell Biol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6307246/ https://ncbi.nlm.nih.gov/pubmed/30587121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12860-018-0180-1 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|